StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) company profile

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$29.98−2.34 (-7.24%)

Close on Nov 17, 2026Market cap $352.37MP/E –Yield –

About Surrozen

Biological Products, (No Diagnostic Substances), SIC 2836

Surrozen is a biotechnology company that discovers and develops antibody-based therapeutics designed to selectively regulate the Wnt signaling pathway for tissue repair. Its operations center on ophthalmology, targeting diseases such as diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema. The company's lead candidates include SZN-8141, SZN-8143, and SZN-413, which aim to restore retinal vascular integrity and inhibit abnormal blood vessel growth. It also conducts preclinical research programs for corneal endothelial injuries and photoreceptor degeneration. Its therapies target patients suffering from serious ocular disorders, and its clients include corporate partners such as Boehringer Ingelheim International GmbH.

Surrozen is located in South San Francisco, California. The company has investigated the biological role of Wnt signaling across more than twenty different tissue types, maintaining a focused pipeline of preclinical ophthalmic programs and entering strategic development agreements with international corporate collaborators.

Summary of the business section of Surrozen's latest annual report, written by StockData.

Company profile

Company

Legal name
Surrozen, Inc./DE
Headquarters
South San Francisco, CA
Address
171 Oyster Point Blvd, Suite 400 94080
Phone
(650) 475-2820
Employees
44, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Francisco, California

Stock & identifiers

Ticker
SRZN
Former tickers
CHFW until Aug 17, 2021
Exchange
Nasdaq
IPO date
Nov 19, 2020
Shares outstanding
12M, Aug 4, 2026
Public float
$59.70M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Dec 14, 2023
SEC CIK
1824893
CUSIP
86889P208
ISIN
US86889P2083
FIGI
BBG00XY94S95
Share class FIGI
BBG00XY94SB2
EIN
30-1374889

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Craig C. ParkerChief Executive Officer, Director18,175
Andrew Pedrum MalekiChief Financial Officer607
Charles O. WilliamsChief Operating Officer18,237
Yang LiExec. Vice President, Research19,584
Tim KutzkeyDirector3,813,501
David J. WoodhouseDirector35,129
Anna BerkenblitDirector35,129
Mace RothenbergDirector35,129
Eric BjerkholtDirector–
Mary Haak-FrendschoDirector35,129
Christopher Y. ChaiDirector35,129
Shao-Lee LinDirector35,129

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.82M$4.81M$1.40M$240–
FY2024$1.52M$1.93M$927.26K$153–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Craig Parker
President and Chief Executive Officer
$630.00K–$262.00K$1.58M$346.50K–$2.82M+85%
Charles Williams
Chief Operating Officer and Corporate Secretary
$485.00K$7.79K$117.90K$711.23K$194.00K$3.00K$1.52M+51%
Yang Li
Executive Vice President, Research
$456.50K–$91.70K$553.18K$182.60K$3.00K$1.29M+52%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Nov 19, 2020
Offer price
$10.00
Securities offered
8,000,000
Gross proceeds
$80.00M
Exchange
NYSE American
First trading day
Jan 11, 2021
First-day close
$10.11+1.1%
Lock-up ends (est.)
Jul 10, 2021

“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-third of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 1, 2026, we had 44 full-time employees, with 27 in research and development and 17 in general and administrative functions.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?